AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AIDS Therapies
New NNRTIs Act Against HIV Resistant To Other NNRTIs
August 23rd, 1999
A new member of a potent class of HIV drugs is active against viral strains resistant to other members of the class. The new nonnucleoside reverse transcriptase inhibitor (NNRTI) is costatolide, the isomer of calanolide A previously known as (-)-calanolide B. New studies show that it is active against HIV with the Y181C point mutation that confers resistance to most NNRTIs. This means that costatolide could be combined with a different NNRTI. Such a combination would require a third drug such as a nucleoside-analog reverse transcriptase inhibitor (NARTI) to ensure against rapid development of resistant HIV. "The possibility of...
Source: AIDS Weekly (1999-08-23)
|
